Viral Vectors and Plasmid DNA Manufacturing market is

Visiongain has published a new report entitled Viral Vectors and Plasmid DNA Manufacturing 2022-2032. It includes profiles of Viral Vectors and Plasmid DNA Manufacturing and Forecasts Market Segment by Vector Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), Market Segment by Application (Antisense & RNAi, Gene Therapy, Cell Therapy, Vaccinology), Market Segment by End-use (Pharma and Biopharma Companies, Research Institutes), Market Segment by Disease (Oncology, Genetic Disorders, Infectious Diseases, Others), Market Segment by Workflow (Upstream, Downstream), plus COVID-19 Impact Analysis and Recovery Pattern Analysis (“V”-shaped, “W”-shaped, “U”-shaped, “L”-shaped), Profiles of Leading Companies, Region and Country.

The viral vectors and plasmid DNA manufacturing market was valued at US$482.3 million in 2021 and is projected to grow at a CAGR of 18.09% during the forecast period 2022-2032.

Challenges Associated with Shortage of Viral Vector Manufacturing Capacities
Due to the rise in clinical-stage start-ups, contract manufacturers, on which new gene & cell therapy enterprises rely for early-stage development activities, are undergoing a shortage of viral vector manufacturing capacities. To avoid the challenges of outsourcing, when these businesses achieve commercial scale, they usually opt to maintain complete control over their manufacturing. As a result, biotech companies started to prepare for growth, organise internal teams, and/or seek advice from site consultants. These experts aid in the hunt for suitable R&D facilities or, increasingly, new construction sites in the markets.

These internal capabilities enable gene & cell therapy enterprises to swiftly scale up manufacturing from clinical quantities to commercial scale, even when therapies are still in the R&D stage. This also enables co-location with R&D operations, enabling a smooth technology transfer with minimal disruption….